Loading…
← CockpitCompetitor Analysis › 300871.SZ Hvsen Biotechnology Co. Ltd. Class AOpen in the cockpit ↗

Hvsen Biotechnology Co. Ltd. Class A300871.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 60
Mkt cap
$553M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$12.6M
20-day average traded
Fwd P/E
11.7×
forward earnings
ROIC−WACC
+1.8 pp
WACC 9.6%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥18.78
1D-0.8%
1W+7.1%
1M+0.1%
3M-19.1%
6M-22.0%
YTD-9.4%
1Y-13.1%
ATR %4.0%
52w lowhigh42.4% off high

What Hvsen Biotechnology does

Employees: 1,133

Hvsen Biotechnology at a glance

Size Hvsen Biotechnology (300871.SZ) is a China Health Care company (Biotechnology) with a market value of $553M, the 3443rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.78 on 18 Nov 2026.

Performance Over six months the shares fell 22.0%, against -13.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.

Growth Revenue grew 2.4% over the last twelve months (peer median +7.7%); the operating margin is 16.9% (peer median -49.9%).

Valuation It trades at 11.7× forward earnings against a peer median of 31.1× (cheapest of 7).

Capital Return on invested capital runs 1.8 points above its cost of capital (9.6% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86300871.SZ 79
Six months, rebased to 100: Hvsen Biotechnology against the median of its 20 peers (local-currency closes).

Hvsen Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.71BCN¥1.68BCN¥1.20BCN¥1.02BCN¥1.02B
Revenue growth—+40%+18%0%—
Gross profitCN¥650MCN¥484MCN¥159MCN¥164MCN¥196M
EBITDAn/aCN¥398MCN¥131MCN¥127MCN¥124M
Net incomeCN¥324MCN¥253M-CN¥20.2MCN¥16.8MCN¥52.7M
Free cash flow-CN¥159MCN¥149M-CN¥143M-CN¥77.2M-CN¥323M
Capital expenditureCN¥420MCN¥96.9MCN¥194MCN¥184MCN¥429M
Total debtCN¥678MCN¥468MCN¥1.20BCN¥1.00BCN¥984M

Quarterly statements and history in the cockpit →

Hvsen Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%SANAWVECLYM3004041521GNFT1672FDMT300318VLASRZN6586300871.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hvsen Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×3004041521GNFT688639603255300871.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hvsen Biotechnology is the large dot.

Hvsen Biotechnology competitors and peer comparison

How Hvsen Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hvsen Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure300871.SZPeer medianRank in peer set
1-month return+0.1%-15.3%5th highest of 21
6-month return-22.0%-13.8%7th lowest of 19
Distance from 52-week high-42.4%-47.6%8th highest of 21
Revenue growth (TTM)+2.4%+7.7%7th lowest of 17
Operating margin16.9%-49.9%2nd highest of 17
Forward P/E11.7×31.1×cheapest of 7
ROIC minus cost of capital+1.8 pp-3.8 pp2nd highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%11.7×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%n/an/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%69.3×31.9%+27.2%
Frontage 1521.HKHong Kong$542M+113%+10%8%24.6×14.3%+15.4%
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%n/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%n/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a

Questions

Which companies are Hvsen Biotechnology's closest peers?
The cockpit's peer set: Sana Biotechnology (SANA), Wave Life Sciences (WVE), Climb Bio (CLYM), Boji Medical Technology (300404.SZ), Frontage (1521.HK), Genfit (GNFT.PA), Ascletis Pharma (1672.HK), 4D Molecular Therapeutics (FDMT).
Is Hvsen Biotechnology expensive compared with its peers?
On forward p/e it trades at 11.7× against a peer median of 31.1×, cheapest of 7 in its peer set.
How has Hvsen Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -22.0% against -13.8% for the median peer; over one year -13.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.